A Study of Oral 7HP349 (Alintegimod) in Combination With Ipilimumab Followed by Nivolumab Monotherapy
7 Hills Pharma, LLC
7 Hills Pharma, LLC
Obsidian Therapeutics, Inc.
Filamon LTD
Replimune Inc.
Bruce Robinson, MD
The Netherlands Cancer Institute
Medicenna Therapeutics, Inc.
Iovance Biotherapeutics, Inc.
Medical Dermatology Specialists
McGill University Health Centre/Research Institute of the McGill University Health Centre
National Cancer Institute (NCI)
National Cancer Institute (NCI)
Klus Pharma Inc.
Revolution Medicines, Inc.
Ludwig Institute for Cancer Research
Exicure, Inc.
Allarity Therapeutics
Dynavax Technologies Corporation
Lumos Pharma
Aprea Therapeutics
Incyte Corporation
Stanford University
Ascend Biopharmaceuticals Ltd
University of Leeds
Icahn School of Medicine at Mount Sinai
University of Utah
University of Pittsburgh
National Institutes of Health Clinical Center (CC)
University of Massachusetts, Worcester
Hadassah Medical Organization
National Institutes of Health Clinical Center (CC)
OHSU Knight Cancer Institute
Skinfrared LLC
National Cancer Institute (NCI)